Pfizer is slated to present the results of the Phase III PALOMA-2 trial, a study designed to confirm the progression-free survival benefits experienced in patients treated with Ibrance (palbociclib) and the hormone therapy letrozole versus hormone therapy alone in the PALOMA-1 Phase II trial that resulted in FDA’s accelerated approval of the drug in early 2015.
Based on the abstract, released by ASCO May 18, the results of PALOMA-2 are impressive, with a median PFS that...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)